Merck 3rd Qtr 2008 Earnings Misses

Merck Reports Third-Quarter 2008 Financial Results
• Company Announces Third-Quarter 2008 Non-GAAP EPS of $0.80, Excluding 29 Cents
of Restructuring Charges; Third-Quarter GAAP EPS of $0.51
• 2008 Global Restructuring Efforts Expected to Reduce Workforce by 12 Percent;
Cumulative Savings of $3.8 to $4.2 Billion Expected from 2008 to 2013 and Pretax Costs
of $1.6 Billion to $2.0 Billion Through 2011
• JANUVIA and JANUMET, Treatments for Type 2 Diabetes, and ISENTRESS, Merck's
HIV Medicine, Deliver Strong Growth as Worldwide Launches Continue
• Merck Anticipates Full-Year 2008 EPS Range of $3.28 to $3.32, Excluding Certain
Items, and GAAP 2008 EPS Range of $3.45 to $3.55
• Merck Anticipates 2005 to 2010 Compound Annual Non-GAAP EPS Growth in Mid-to-
High Single-Digits, Excluding Certain Items; GAAP EPS Compound Annual Growth Rate
Expected to Increase by Double-Digits Over Same Period

WHITEHOUSE STATION, N.J., Oct. 22, 2008 – Merck & Co., Inc. today announced financial
results for the third quarter of 2008, provided financial guidance for 2008 and 2010, and outlined additional steps in its continuing efforts to position the Company for success in a rapidly
evolving industry.
Merck reported non-GAAP (generally accepted accounting principles) earnings per
share (EPS) of $0.80 for the third quarter of 2008, excluding $0.29 of restructuring charges.
GAAP EPS for the third quarter were $0.51. Third quarter worldwide sales were $5.9 billion, a
decrease of 2 percent from the third quarter of 2007. Foreign exchange for the third quarter
favorably affected global sales performance by 4 percent. Net income for the third quarter of
2008 was $1,092.7 million compared with $1,525.5 million in the third quarter of 2007, which
include aftertax restructuring charges of $612 million and $117 million, respectively. For the first
nine months of 2008, worldwide sales were $17.8 billion and net income was $6,163.6 million.